IRIDEX Announces Multiple Studies of MicroPulse® Laser Therapy Published at World Ophthalmology Congress > IRIDEX



MOUNTAIN VIEW, Calif., June 25, 2018 -- IRIDEX Corporation (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, today announced new data was released at the World Ophthalmology Congress in Barcelona, Spain showing that MicroPulse® Laser Therapy with the MicroPulse P3™ Glaucoma Device is safe and effective. New real-world data shows a reduction in IOP close to 50%, with new morphological information elucidating the mechanism of action of the procedure.

Ihab Ibrahim Massad, FICO, MD, presented “No More Blades, Scars or Scares: A One Year Experience of MicroPulse Trans-scleral Cyclophotocoagulation from Middle East,” a retrospective chart review of 67 eyes that were treated with MP-TSCPC at a hospital in Jordan. The analysis found that IOP decreased close to 50%, from a mean preoperative IOP of 34.70 mmHg to a mean postoperative IOP of 18.32 mmHg at 1 month and 16.90 mmHg at 12 months. In addition, ocular hypertensive medication use was lowered from 3.45 medications to 2.64 medications at 1 month and 12 months. Only one-third of the eyes in the study had primary open-angle glaucoma, showing the flexibility of the procedure.

Shotar Asano, MD, and colleagues in Japan presented, “IOP Reduction and Morphological Changes of the Ciliary Body by MicroPulse Transscleral Cyclophotocoagulation.” The authors investigated postoperative morphological changes of the ciliary body using anterior segment optical coherence tomography (AS-OCT) in eight eyes with refractory glaucoma. AS-OCT analysis revealed that ciliochoroidal effusion (CE) was observed in four out of eight eyes in the inferior sclera at one day after the procedure, and all CE disappeared by two weeks after the procedure.

Tim Buckley, Vice President of Global Marketing and Business Development at IRIDEX explained, “It has long been understood that laser treatment of the ciliary processes will decrease production of aqueous humor. This study shows that there may be an additional mechanism of action in play as well. This speaks to why MP-CPC works so well in a large variety of patients with different types of glaucoma.”

Glaucoma is the second most common cause of blindness in the world, and surgical interventions are not always possible for certain patients. MicroPulse Cyclophotocoagulation (CPC) is a safe and effective treatment option for a variety of types of glaucoma, and it can be performed either in the operating room or as an outpatient, office-based procedure. Learn more at

The World Ophthalmology Congress is the meeting of the International Council of Ophthalmology and welcomes over 12,000 delegates from more than 100 countries. The meeting includes a scientific program of over 350 sessions addressing all subspecialties and related interests in ophthalmology with 45 Sub-specialty, 39 National, five Regional and four Supranational Societies participating in the program.


IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit

Media Contact:

Jamie Hall
Pascale Communications, LLC.

Investor Relations Contact:

Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404

Posted in: News
Actions: E-mail | Permalink |